The TRIUMPH-4 safety profile is qualitatively similar to semaglutide and tirzepatide (GI adverse events dominate) but the rate of nausea, vomiting, and diarrhea is higher than previously seen in the class, and dropout at 12 mg is higher than at 9 mg
Issues such as gastroparesis, intestinal obstructions, and pancreatitis have been confirmed by recent research and advisories from the Food and Drug Administration (FDA)
The database contains de-identified inpatient and outpatient information, provided with informed consent [15], on more than 63 million patients from multiple healthcare systems [16]
PlatonALSteleaCGBoiteanuOPatrascanuEZetuINRouSNet al
Alternative approaches if alternating is not right for you For many people, the complications of alternating outweigh the potential benefits
It is a synthetic analog of human GLP-1 with amino-acid substitutions and a fatty-acid side chain to extend half-life via albumin binding